Display options
Cite
Valvassori SS, Gava FF, Dal-Pont GC, et al. Effects of lithium and valproate on ERK/JNK signaling pathway in an animal model of mania induced by amphetamine. Heliyon. 2019;5(5):e01541doi: 10.1016/j.heliyon.2019.e01541.
Valvassori, S. S., Gava, F. F., Dal-Pont, G. C., Simões, H. L., Damiani-Neves, M., Andersen, M. L., Boeck, C. R., & Quevedo, J. (2019). Effects of lithium and valproate on ERK/JNK signaling pathway in an animal model of mania induced by amphetamine. Heliyon, 5(5), e01541. https://doi.org/10.1016/j.heliyon.2019.e01541
Valvassori, Samira S, et al. "Effects of lithium and valproate on ERK/JNK signaling pathway in an animal model of mania induced by amphetamine." Heliyon vol. 5,5 (2019): e01541. doi: https://doi.org/10.1016/j.heliyon.2019.e01541
Valvassori SS, Gava FF, Dal-Pont GC, Simões HL, Damiani-Neves M, Andersen ML, Boeck CR, Quevedo J. Effects of lithium and valproate on ERK/JNK signaling pathway in an animal model of mania induced by amphetamine. Heliyon. 2019 May 15;5(5):e01541. doi: 10.1016/j.heliyon.2019.e01541. eCollection 2019 May. PMID: 31193305; PMCID: PMC6525279.
Copy Download .nbib Format: NLM
Share it on

Heliyon. 2019 May 15;5(5):e01541. doi: 10.1016/j.heliyon.2019.e01541. eCollection 2019 May.

Effects of lithium and valproate on ERK/JNK signaling pathway in an animal model of mania induced by amphetamine.

Heliyon

Samira S Valvassori, Fernanda F Gava, Gustavo C Dal-Pont, Henio Leonardo Simões, Marcela Damiani-Neves, Monica Levy Andersen, Carina Rodrigues Boeck, João Quevedo

Affiliations

  1. Translational Psychiatry Laboratory, Graduate Program in Health Sciences, University of Southern Santa Catarina (UNESC), Criciúma, SC, Brazil.
  2. Master's Degree in Health and Life Sciences, Postgraduate Program in Nanosciences, Franciscan University, Santa Maria, RS, Brazil.
  3. Department of Psychobiology, Universidade Federal de São Paulo, São Paulo, Brazil.
  4. Translational Psychiatry Program, Department of Psychiatry and Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth), Houston, TX, USA.
  5. Center of Excellence on Mood Disorders, Department of Psychiatry and Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth), Houston, TX, USA.
  6. Neuroscience Graduate Program, The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX, USA.

PMID: 31193305 PMCID: PMC6525279 DOI: 10.1016/j.heliyon.2019.e01541

Abstract

Bipolar disorder (BD) is a severe and chronic psychiatric disorder, characterized by recurrent mood episodes of depression and mania. Some studies have indicated that there are ERK and JNK pathways alterations in the brain from bipolar patients. The animal model of mania induced by dextroamphetamine (d-AMPH) has been considered an excellent model to study intracellular alterations related to BD. The present study aimed to evaluate the effects of lithium (Li) and valproate (VPA) on the behavioral and ERK1/2/JNK1/2 signaling pathway in an animal model of mania induced by d-AMPH. Wistar rats were first given d-AMPH or saline (Sal) for 14 days, and then, between the 8th and 14th days, the rats were treated with Li, VPA, or Sal. The open-field test was used to evaluate the locomotion and exploration behaviors of rats. The levels of phosphorylated ERK1/2 and JNK1/2 were assessed in the hippocampus and frontal cortex of the rats. Li and VPA reversed the increased of locomotion and exploration induced by d-AMPH. The treatment with VPA or AMPH

Keywords: Molecular biology; Neuroscience

References

  1. Science. 2000 May 5;288(5467):870-4 - PubMed
  2. Ann N Y Acad Sci. 2000 Sep;914:238-62 - PubMed
  3. Behav Brain Res. 2001 Jan 8;118(1):95-105 - PubMed
  4. Curr Opin Neurobiol. 2001 Jun;11(3):297-305 - PubMed
  5. J Biol Chem. 2001 Aug 24;276(34):31674-83 - PubMed
  6. Mol Pharmacol. 2002 Nov;62(5):993-1000 - PubMed
  7. Science. 2002 Dec 6;298(5600):1911-2 - PubMed
  8. J Neurochem. 2003 Feb;84(3):566-75 - PubMed
  9. J Biol Chem. 1951 Nov;193(1):265-75 - PubMed
  10. J Neurosci. 2004 Jul 21;24(29):6590-9 - PubMed
  11. J Neurochem. 2004 Oct;91(2):337-48 - PubMed
  12. Proc Natl Acad Sci U S A. 2005 Jan 11;102(2):491-6 - PubMed
  13. J Affect Disord. 2005 Apr;85(3):259-66 - PubMed
  14. Mol Neurobiol. 2005 Oct;32(2):173-202 - PubMed
  15. Biol Psychiatry. 2006 Jun 1;59(11):1006-20 - PubMed
  16. Bipolar Disord. 2006 Jun;8(3):275-80 - PubMed
  17. Curr Opin Pharmacol. 2007 Feb;7(1):22-6 - PubMed
  18. Schizophr Res. 2007 Aug;94(1-3):273-80 - PubMed
  19. J Neurochem. 2007 Oct;103(2):706-13 - PubMed
  20. Neuropharmacology. 2007 Sep;53(4):487-95 - PubMed
  21. J Pharmacol Exp Ther. 2008 Sep;326(3):838-48 - PubMed
  22. Neurobiol Dis. 2008 Sep;31(3):355-60 - PubMed
  23. J Psychiatry Neurosci. 2009 Jul;34(4):263-71 - PubMed
  24. Biol Psychiatry. 2010 Jan 15;67(2):186-8 - PubMed
  25. J Affect Disord. 2010 Jul;124(1-2):164-9 - PubMed
  26. Neurobiol Dis. 2010 Mar;37(3):596-603 - PubMed
  27. J Psychiatr Res. 2010 Jun;44(8):506-10 - PubMed
  28. Neuropsychopharmacology. 2010 Jul;35(8):1761-74 - PubMed
  29. Neurosci Lett. 2010 Sep 20;482(1):51-6 - PubMed
  30. Pharmacol Ther. 2010 Nov;128(2):281-304 - PubMed
  31. J Pineal Res. 2010 Nov;49(4):382-9 - PubMed
  32. Neurosci Biobehav Rev. 2011 Jan;35(3):804-17 - PubMed
  33. Neuroimage. 2011 Feb 14;54(4):2643-51 - PubMed
  34. Int J Neuropsychopharmacol. 2011 Sep;14(8):1075-89 - PubMed
  35. Br J Pharmacol. 2011 Oct;164(4):1263-84 - PubMed
  36. J Immunotoxicol. 2011 Jul-Sep;8(3):210-8 - PubMed
  37. J Neurosci Res. 2011 Oct;89(10):1666-75 - PubMed
  38. Am J Psychiatry. 2012 Aug;169(8):831-40 - PubMed
  39. Psychoneuroendocrinology. 2013 May;38(5):667-76 - PubMed
  40. Neurobiol Dis. 2013 Feb;50:49-58 - PubMed
  41. J Psychopharmacol. 2012 Dec;26(12):1594-604 - PubMed
  42. J Neuroinflammation. 2013 Apr 05;10:45 - PubMed
  43. PLoS One. 2013 Nov 04;8(11):e78386 - PubMed
  44. Brain Res. 2014 Mar 25;1555:1-9 - PubMed
  45. JAMA Psychiatry. 2014 Nov;71(11):1222-30 - PubMed
  46. Mol Psychiatry. 2015 Aug;20(8):931-40 - PubMed
  47. J Psychiatr Res. 2015 Feb;61:114-21 - PubMed
  48. J Affect Disord. 2014 Dec;169 Suppl 1:S12-6 - PubMed
  49. J Recept Signal Transduct Res. 2015;35(6):600-4 - PubMed
  50. Eur Neuropsychopharmacol. 2016 Aug;26(8):1310-9 - PubMed
  51. Neuropharmacology. 2017 May 1;117:447-459 - PubMed
  52. Mol Neurobiol. 2018 Feb;55(2):1430-1439 - PubMed
  53. Biomed Res Int. 2017;2017:8124501 - PubMed
  54. Bipolar Disord. 2017 Mar;19(2):74-83 - PubMed
  55. Clin Drug Investig. 2017 Aug;37(8):713-727 - PubMed
  56. Int J Neuropsychopharmacol. 2017 Nov 1;20(11):877-885 - PubMed
  57. Psychiatry Res. 1985 Dec;16(4):303-8 - PubMed
  58. Drug Saf. 1995 Feb;12(2):146-53 - PubMed
  59. Nature. 1994 May 12;369(6476):156-60 - PubMed
  60. Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):13290-5 - PubMed

Publication Types